Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical plans to buy spinal cord stimulation company Nevro for about $250 million, the companies announced on Thursday. Globus will pay $5.85 per share in an all-cash purchase, a 27% ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. The all-cash deal comes ...

22, 2015 /PRNewswire/ -- Nevro Corp. (NYSE ... of its Premarket Approval Application (PMA) for the Senza spinal cord stimulation (SCS) system. According to the approvable letter, approval ...

Following strong financial results revealed last month, US-headquartered Globus Medical has agreed to acquire spinal cord stimulation (SCS) company Nevro for $250m to reinforce its position in the ...

Nevro has developed and commercialized the Senza spinal cord stimulation (SCS ... and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy.

Nevro's comprehensive HFX™ spinal cord stimulation (SCS ... Senza®, Senza II®, Senza Omnia™, and HFX iQ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy.

Nevro's comprehensive HFX™ spinal cord stimulation (SCS ... Senza®, Senza II®, Senza Omnia™, and HFX iQ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy.